MedTrace Logo

Pentoxifylline in Treatment of Patients With Nonalcoholic Steatohepatitis

NCT05284448 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2024-06-21

No results posted yet for this study

Summary

The aim of the present study is to evaluate the efficacy and safety of pentoxifylline in the treatment of non-alcoholic steatohepatitis patients.

Conditions

  • NASH - Nonalcoholic Steatohepatitis

Interventions

DRUG

pentoxifylline (Trental SR®)

400 mg three times daily

Sponsors & Collaborators

  • Al-Azhar University

    lead OTHER

Principal Investigators

  • Zeinab Zalat, PhD · Professor and Head of Clinical Pharmacy Department, Faculty of Pharmacy, Al-Azhar University(Girls, Cairo)

  • Adel Gaber Bakr, PhD · Assistant Professor of Pharmacology and Toxicology, Al-Azhar University (Boys, Assiut)

  • Ahmed ElGhandour, MD · Assistant Professor of Internal Medicine and Gastroenterology, Faculty of Medicine, Ain-Shams University

  • ahmed abomandour, Demonstrator · Demonstrator of Clinical Pharmacy Department, Faculty of Pharmacy, Al-Azhar University (Boys, Assiut)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-01
Primary Completion
2022-09-01
Completion
2022-10-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05284448 on ClinicalTrials.gov